Trial (reference) and trial groups | Randomisation model and inclusion years | Start ages (years) | Participation rate | PSA cut-off (ng/ml) | Ancillary test | Pre-biopsy MRI | Standard biopsy protocol | Primary outcome |
Number of men | ||||||||
ProScreen109 | Before consent 2018– | Yes | PCa mortality | |||||
Screening group | 29 000 | 50–63 | 52%* | 3.0 | 4KScore | Yes | TBx+SBx | |
Control group | 88 000 | Clinical routine | – | Clinical routine | – | |||
Gothenburg-292 | Before consent 2015–2020 | 50–60 | Yes | Clinically insignificant PCa | ||||
Screening group | 39 000 | 47% | ||||||
Screening arm 1 | 3.0 | – | Yes | SBx+TBx | ||||
Screening arm 2 | 3.0 | – | Yes | TBx | ||||
Screening arm 3 | 1.8 | – | Yes | TBx | ||||
Control group | 19 000 | Clinical routine | – | Clinical routine | – | |||
PROBASE94 | After consent 2014–2019 | 11% | Yes | Metastatic PCa age 60 | ||||
Early screening start | 23 000 | 45 | 3.0 | – | Yes | TBx+SBx | ||
Standard start age | 23 000 | 50 | 3.0 | – | Yes | TBx+SBx |
*Inclusion is ongoing.
PCa, prostate cancer; PSA, prostate-specific amtigen; SBx, systematic biopsy; TBx, targeted biopsy.